DEFINIUM THERAPEUTICS, INC.

NASDAQ: DFTX (Definium Therapeutics, Inc.)

Last update: 6 hours ago

28.34

-1.14 (-3.87%)

Previous Close 29.48
Volume 3,238,037
Avg. Volume (3M) 2,163,526
Market Cap 4,837,210,112
Price / Book 4.54
52 Weeks Range
10.53 (-62%) — 49.70 (75%)
Earnings Date 5 Nov 2026

AIStockmoo Score

0.0
Earns below its cost of capital. Returns on capital rising. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Financial Health info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Uptrend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. Volume is heavier on down days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
Holdings' Sentiment info NA
Institutions net +8.02% of shares in their latest 13F filings: 216 holders increased, 167 decreased (quarter to 30 Sep 2026). info
Short interest -2.3% from 31 Aug to 30 Oct 2026, 5.8 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Earnings per share have mostly fallen. Made a loss in recent years. info
Below its medium-term trend line. info
Price is near its 52-week average. Down over 5 years. info
Short-term momentum falling. info
Price is near resistance. Levels trending down. info
Final Score -0.01
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Definium Therapeutics, Inc. Mixed -

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
DFTX 5 B - - 4.54 0.0
SYRE 9 B - - 10.08 1.1
MDGL 9 B - - 14.74 -0.4
CORT 7 B - 47.78 8.89 -1.5
FOLD 5 B - - - 0.0
TARS 4 B - - 36.00 0.6

Select this tab to load the latest available analysis.

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth

Ownership

Name Date Shares Held
Capital World Investors 30 Sep 2026 8,255,584
Octagon Capital Advisors Lp 30 Sep 2026 2,511,000
Alliancebernstein L.P. 30 Sep 2026 1,938,303

No data within this time range.

Institutions

Institutional ownership: 92.20%

Positions Holders Shares
Increased 216 29,390,198
Decreased 167 18,014,338
New 70 8,825,116
Sold out 70 9,208,628

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 9,613,993 5.8
15 Oct 2026 10,044,279 4.9
30 Sep 2026 11,344,959 4.9
15 Sep 2026 11,785,195 5.2
31 Aug 2026 9,836,400 5.6
14 Aug 2026 8,969,420 3.4

FINRA short interest via Nasdaq, reported twice a month.

6 Positive 0 Negative 6 Neutral
Date Type Details
20 Nov 2026 Yahoo Finance Definium Therapeutics Eyes 2027 FDA Filing for LSD-Based Drug, Weighs Two Treatment Paths
Definium Therapeutics (NASDAQ:DFTX) expects to file a new drug application for its lead LSD-based treatment in the first half of 2027, though the company has not settled on whether to seek approval for generalized anxiety disorder, major depressive disorder or both at the outset. CEO Rob Barrow sai…
16 Nov 2026 Yahoo Finance Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
Two encouraging changes from five patients hint at a pipeline beyond depression and anxiety, but the early-stage data leaves open whether DT402 can carry that weight.
16 Nov 2026 Yahoo Finance Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Village Farms Posted Record Cannabis Revenue as International Exports Surged 75% Auxly Cannabis Delivered Record Q3 Revenue as Adjusted EBITDA Climbed 29% Key Takeaways; Psychedelic Sector Definium Therapeutics Reported Strong Q3 Results as DT120 Advanced Towards…
12 Nov 2026 Yahoo Finance Is Definium Therapeutics (DFTX) Fully Priced After Positive Phase 3 Results?
Definium Therapeutics has seen its stock price move sharply in recent years, and the surge now raises a straightforward question for investors who care about balance sheet strength. Is the current market value still grounded in Definium Therapeutics' book value, or has the share price pulled…
11 Nov 2026 Yahoo Finance How Investors May Respond To Definium Therapeutics Stock After Phase 3 Success
Definium Therapeutics reported positive Phase 3 data for DT120 in generalized anxiety disorder and major depressive disorder, alongside plans to seek FDA approval after multiple pivotal studies. Recent earnings showed ongoing net losses tied to development spend. The most distinctive angle is that…
11 Nov 2026 Yahoo Finance Definium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story Intact
Definium Therapeutics (DFTX) is back in focus after reporting third quarter results that showed a reduced quarterly net loss alongside a much larger cumulative loss for the first nine months of 2026. Definium Therapeutics has ridden a sharp re-rating over 2026, with the share price delivering a…
11 Nov 2026 Yahoo Finance Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies
Definium Therapeutics (NASDAQ:DFTX) plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said. The company intends to s…
10 Nov 2026 Yahoo Finance Definium Therapeutics Inc (DFTX) (Q3 2026) Earnings Call Highlights: $1. ...
Definium Therapeutics Inc (DFTX) pairs a cash runway into 2030 with two FDA breakthrough therapy designations for DT120 and a planned first-half 2027 NDA filing, even as R&D and G&A spending climb.
09 Nov 2026 Yahoo Finance Definium (DFTX) Q3 2026 Earnings Call Transcript
Phase 3 wins set up a 2027 filing and a commercial push.
09 Nov 2026 Yahoo Finance What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
Definium Therapeutics (NASDAQ:DFTX) plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized anxiety disorder and major depressive disorder, executives said on the company’s…
09 Nov 2026 Yahoo Finance Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
NEW YORK, November 09, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported…
09 Nov 2026 Yahoo Finance Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK, November 09, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of…
04 Nov 2026 Yahoo Finance Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
NEW YORK, November 04, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced four…
03 Nov 2026 Yahoo Finance Definium Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK, November 03, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that…
29 Oct 2026 Yahoo Finance Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
NEW YORK, October 29, 2026--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30…
19 Oct 2026 Yahoo Finance Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value
Definium Therapeutics has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$32.97 level is supported by the book value on its balance sheet. With such a strong price story already on the table, investors are asking how much of that journey is…
30 Sep 2026 Yahoo Finance Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward…
Show more

Technical Setup Medium

Trend order
Slope
Entry
Volume
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. Volume is heavier on down days.
Nearest support: 25.76 – 26.74 · moderate level
Nearest resistance: 29.68 – 30.66 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria